AMES, IA--(Marketwire - February 09, 2009) - BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a producer of products and solutions for academic researchers and
commercial users based upon its ultra-micro to nano scale fluid deposition
platform, today announced the first ever sale of a Nano eNabler™ System
to a commercial user. The sale to an international semiconductor
manufacturer was completed by BioForce's Continental European distributor,
NanoandMore GmbH.
In addition to the significant milestone of being the first Nano eNabler
System sale to a commercial user, this transaction marks the first sale to
a user who intends to deploy the Nano eNabler in a production rather than
research laboratory environment. This reinforces BioForce's vision that a
need exists for the Nano eNabler in production environments where
commercial users seek to manufacture products, such as biosensors and other
diagnostic devices, requiring ultra-micro to nano scale fluid deposition.
NanoandMore GmbH's Chief Executive Officer, Peer Burshille, said, "We are
continuing to see significant interest among European sales prospects in
the Nano eNabler's unique capabilities. This interest comes from both
academic institutions and industrial companies. This marks our company's
fifth Nano eNabler System sale, and we expect that our sales of BioForce's
products in 2009 will exceed those of previous years."
"The fact that this semiconductor manufacturer has made this capital
investment during an economic climate when many companies are deferring
capital expenditures demonstrates that the Nano eNabler is essential in
order for strategically important advances to be made in both biological
and non-biological areas."
BioForce's Chief Executive Officer, Kerry Frey, said, "I see this
transaction as significant as it involves a commercial user whose
production requirements could result in a need for multiple Nano eNabler
systems. Establishing that there is a market for the Nano eNabler as a
production tool has been one of our key objectives, and is a cornerstone of
our long-term business plan. It is indeed gratifying to have achieved this
important milestone."
For further information about this release please contact Greg Brown, Chief
Financial Officer of BioForce at (515) 233-8333 ext. 118, or Rich Kaiser,
Investor Relations at (800) 631-8127.
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences produces products and solutions for academic
researchers and industrial companies based upon its ultra-micro to nano
scale fluid deposition platform. BioForce's flagship product, the Nano eNabler™
molecular printer, gives the Company and its customers a platform for
development and discovery by depositing fluid onto surfaces with nanometer
spatial precision. BioForce technology is being used in biological areas
such as biosensor
functionalization; patterning and cell
adhesion; and the printing of
proteins to guide neural cell growth, as well as in non-biological
applications. For more information, visit http://www.bioforcenano.com or
call 515-233-8333.
This news release contains forward-looking information that may be affected
by certain risks and uncertainties, including those risks and uncertainties
described in BioForce Nanosciences' most recent filings with the Securities
and Exchange Commission. BioForce Nanosciences' actual results could differ
materially from such forward-looking statements. BioForce assumes no duty
to update these statements at any future date.
